Merck & Co., Inc. (NYSE:MRK) Stock Price Breaks Above 50-Day Moving Average After Analyst Downgrade

Merck & Co., Inc. (NYSE:MRK) crossed above its 50 day moving average during trading on Friday after JPMorgan Chase & Co. raised their price target on the stock from $165.00 to $175.00. The stock has a 50 day moving average of $146.90 and traded as high as $151.35. JPMorgan Chase & Co. currently has an overweight rating on the stock. Merck & Co., Inc. shares last traded at $149.75, with a volume of 12,341,136 shares changing hands.

MRK has been the subject of a number of other reports. Daiwa Securities Group upgraded Merck & Co., Inc. from a “neutral” rating to an “outperform” rating and set a $143.00 price objective for the company in a research note on Wednesday, August 12th. Guggenheim lifted their target price on Merck & Co., Inc. from $170.00 to $171.00 and gave the company a “buy” rating in a research note on Friday. Cantor Fitzgerald boosted their target price on shares of Merck & Co., Inc. from $120.00 to $145.00 and gave the stock a “neutral” rating in a report on Thursday, October 8th. Weiss Ratings upgraded shares of Merck & Co., Inc. from a “hold (c-)” rating to a “hold (c)” rating in a report on Tuesday, August 25th. Finally, Scotiabank increased their price target on shares of Merck & Co., Inc. from $155.00 to $180.00 and gave the company a “sector outperform” rating in a research report on Tuesday, September 29th. Seventeen analysts have rated the stock with a Buy rating, nine have given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $153.36.

Insider Buying and Selling at Merck & Co., Inc.

In other Merck & Co., Inc. news, EVP Chirfi Guindo sold 10,000 shares of Merck & Co., Inc. stock in a transaction on Thursday, August 13th. The shares were sold at an average price of $135.00, for a total value of $1,350,000.00. Following the completion of the transaction, the executive vice president owned 36,613 shares of the company’s stock, valued at approximately $4,942,755. The trade was a 21.45% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, EVP David Williams sold 52,847 shares of Merck & Co., Inc. stock in a transaction on Wednesday, August 5th. The shares were sold at an average price of $128.77, for a total transaction of $6,805,108.19. Following the completion of the transaction, the executive vice president directly owned 31,716 shares of the company’s stock, valued at $4,084,069.32. The trade was a 62.49% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders have sold 228,238 shares of company stock worth $29,977,783. 0.17% of the stock is currently owned by insiders.

Merck & Co., Inc. News Roundup

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Strong Q3 results and raised outlook: Merck reported adjusted earnings of $2.49 per share versus the $2.09 analyst consensus, while revenue rose 4.7% year over year to $18.09 billion, ahead of estimates. Management raised its 2026 sales and adjusted-profit outlook, providing the main catalyst for the stock’s advance. Merck tops quarterly estimates and hikes profit outlook
• Positive Sentiment: Growth beyond Keytruda: Keytruda, including the newer Qlex formulation, delivered stronger-than-expected sales, while WINREVAIR continued to expand rapidly. Newer product launches are helping offset losses from generic competition and support Merck’s growth outlook. Merck Q3 earnings call highlights pipeline progress and raised outlook
• Positive Sentiment: Pipeline progress: Positive Phase 3 endometrial-cancer data for Keytruda and sacituzumab tirumotecan, along with FDA priority review for the latter, strengthens confidence in Merck’s oncology pipeline and its ability to address future revenue pressure. Merck Phase 3 endometrial cancer data and FDA review
• Positive Sentiment: Supportive analyst action: Guggenheim raised its price target to $171 and maintained a buy rating, indicating additional potential upside based on the earnings and pipeline outlook.

Institutional Investors Weigh In On Merck & Co., Inc.

A number of institutional investors have recently modified their holdings of MRK. Round Rock Advisors LLC boosted its position in shares of Merck & Co., Inc. by 0.7% in the 2nd quarter. Round Rock Advisors LLC now owns 9,901 shares of the company’s stock valued at $1,272,000 after purchasing an additional 66 shares during the period. Cypress Wealth Services LLC grew its stake in Merck & Co., Inc. by 0.5% during the 3rd quarter. Cypress Wealth Services LLC now owns 13,807 shares of the company’s stock worth $1,960,000 after buying an additional 69 shares during the last quarter. Code Waechter LLC increased its position in Merck & Co., Inc. by 3.4% during the third quarter. Code Waechter LLC now owns 2,179 shares of the company’s stock worth $317,000 after buying an additional 71 shares during the period. Cascade Financial Partners LLC increased its position in Merck & Co., Inc. by 0.5% during the second quarter. Cascade Financial Partners LLC now owns 14,746 shares of the company’s stock worth $1,895,000 after buying an additional 80 shares during the period. Finally, Somerset Trust Co lifted its stake in Merck & Co., Inc. by 0.9% in the second quarter. Somerset Trust Co now owns 8,701 shares of the company’s stock valued at $1,118,000 after buying an additional 81 shares during the last quarter. 76.07% of the stock is currently owned by institutional investors and hedge funds.

Merck & Co., Inc. Stock Performance

The company has a market cap of $369.46 billion, a PE ratio of 154.38, a PEG ratio of 6.38 and a beta of 0.21. The stock has a 50 day simple moving average of $146.90 and a two-hundred day simple moving average of $126.69. The company has a debt-to-equity ratio of 1.22, a current ratio of 1.32 and a quick ratio of 1.10.

Merck & Co., Inc. (NYSE:MRK) last announced its earnings results on Thursday, October 29th. The company reported $2.49 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.09 by $0.40. The business had revenue of $18.09 billion for the quarter, compared to analyst estimates of $17.33 billion. Merck & Co., Inc. had a net margin of 3.64% and a return on equity of 16.56%. The company’s revenue for the quarter was up 4.7% compared to the same quarter last year. During the same period last year, the firm posted $2.58 earnings per share. Equities analysts predict that Merck & Co., Inc. will post 2.80 EPS for the current year.

About Merck & Co., Inc.

Merck & Co, Inc is a global healthcare company that develops, manufactures and markets prescription medicines, vaccines and animal-health products. Its pharmaceutical business focuses on oncology, infectious diseases, cardiology, immunology and other areas of significant medical need. The company serves patients, healthcare providers and institutions in markets worldwide.

Merck’s principal products include Keytruda, an immunotherapy used to treat a range of cancers; Gardasil and Gardasil 9, vaccines that help protect against human papillomavirus; and Januvia and Janumet, medicines used to manage type 2 diabetes.